RPRX vs ZTS: stock comparison and AI forecast
Royalty Pharma Plc (RPRX) and Zoetis Inc. (ZTS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
RPRX Royalty Pharma Plc
- Market Cap
- $28.77B
- P/E Ratio
- 38.4x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
ZTS Zoetis Inc.
- Market Cap
- $34.37B
- P/E Ratio
- 13.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ZTS is 1.2 times larger than RPRX by market capitalization ($34.37B against $28.77B).
- ZTS trades at 13.7 times trailing earnings, RPRX at 38.4 times.
- RPRX turns 32.1% of its revenue into net income, against 27.5% for ZTS.
- ZTS carries 3.79 times debt per unit of equity, against 1.47 times for RPRX.
- ZTS yields 2.59% in dividends and RPRX 1.39%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | RPRX | ZTS |
|---|---|---|
| Market Cap | $28.77B | $34.37B |
| P/E Ratio | 38.39x | 13.70x |
| P/B Ratio | 4.21x | 10.92x |
| Dividend Yield | 1.39% | 2.59% |
| EPS | $1.75 | $6.07 |
| Book Value/Share | $15.95 | $7.62 |
| Revenue/Share | $5.92 | $23.03 |
| FCF/Share | – | $5.73 |
Profitability & Margins
| Metric | RPRX | ZTS |
|---|---|---|
| ROE | 11.9% | 83.1% |
| ROA | 4.1% | 17.4% |
| ROIC | 7.9% | – |
| Gross Margin | – | 71.5% |
| Operating Margin | 59.6% | – |
| Net Margin | 32.1% | 27.5% |
| EBT Margin | 53.2% | 34.4% |
| Tax Rate | 0.0% | 20.1% |
Financial Health
| Metric | RPRX | ZTS |
|---|---|---|
| Current Ratio | 2.80x | 3.08x |
| Quick Ratio | – | 1.84x |
| D/E Ratio | 1.47x | 3.79x |
| Financial Leverage | 2.90x | 4.79x |
| Interest Coverage | 0.7x | – |
| Working Capital | $1.13B | $4.29B |
Cash Flow
| Metric | RPRX | ZTS |
|---|---|---|
| Operating Cash Flow | $2.98B | $2.89B |
| Free Cash Flow | – | $2.37B |
| Capital Spending | – | -$521M |
| OCF Growth YoY | 23.7% | -1.4% |
| FCF Growth YoY | – | 6.6% |
| FCF/Sales | – | 24.9% |
| CapEx/Sales | – | 5.5% |
Operational Efficiency
| Metric | RPRX | ZTS |
|---|---|---|
| Asset Turnover | 0.13x | 0.63x |
| Receivables Turnover | – | 6.1x |
| Inventory Turnover | – | 1.1x |
| Fixed Assets Turnover | – | 2.5x |
| Days Sales Outstanding | – | 60 days |
| Days Inventory | – | 347 days |
| Payables Period | – | 61 days |
| Cash Conversion Cycle | – | 346 days |
Income Statement
| Metric | RPRX | ZTS |
|---|---|---|
| Total Revenue | $2.54B | $9.52B |
| Operating Income | $1.51B | – |
| Net Income | $815M | $2.62B |
| R&D Expense | $239M | $722M |
| SG&A Expense | – | $2.38B |
| Cost of Goods Sold | – | $2.71B |
Dividend & Shareholder Information
| Metric | RPRX | ZTS |
|---|---|---|
| Dividends Per Share | $0.93 | $2.15 |
| Payout Ratio | 53.1% | 35.4% |
| Shares Outstanding | 428M | 413M |
| Net Income Growth | -20.2% | 0.1% |
| EPS Growth | 0.0% | 4.5% |
RPRX vs ZTS: stock comparison and AI forecast
Which is bigger, RPRX or ZTS?
ZTS is 1.2 times larger than RPRX by market capitalization ($34.37B against $28.77B).
Which is cheaper on earnings, RPRX or ZTS?
ZTS trades at 13.7 times trailing earnings, RPRX at 38.4 times.
Which one does Intratio's AI model rank higher, RPRX or ZTS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.